Cargando…

Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma

Detalles Bibliográficos
Autores principales:	Martinez-Lopez, J, Sanchez-Vega, B, Barrio, S, Cuenca, I, Ruiz-Heredia, Y, Alonso, R, Rapado, I, Marin, C, Cedena, M-T, Paiva, B, Puig, N, Mateos, M-V, Ayala, R, Hernández, M-T, Jimenez, C, Rosiñol, L, Martínez, R, Teruel, A-I, Gutiérrez, N, Martin-Ramos, M-L, Oriol, A, Bargay, J, Bladé, J, San-Miguel, J, Garcia-Sanz, R, Lahuerta, J-J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467041/ https://www.ncbi.nlm.nih.gov/pubmed/28210002 http://dx.doi.org/10.1038/leu.2017.58

Ejemplares similares

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
por: Rodríguez-Otero, Paula, et al.
Publicado: (2019)

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma
por: Puig, Noemí, et al.
Publicado: (2022)

Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma
por: Puig, Noemí, et al.
Publicado: (2021)

P845: IDENTIFICATION OF MULTIPLE MYELOMA BIOMARKERS VIA LIQUID BIOPSY BASED ON CELL-FREE DNA USING A CAPTURE-HYBRIDIZATION PANEL
por: Buenache Cuenda, N., et al.
Publicado: (2022)

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
por: Medina, Alejandro, et al.
Publicado: (2020)

Measurable residual disease in multiple myeloma: ready for clinical practice?
por: Burgos, Leire, et al.
Publicado: (2020)

Impact of IPSS-M implementation in real-life clinical practice
por: Zamanillo, Irene, et al.
Publicado: (2023)

P702: APPLICATION OF NEXT GENERATION SEQUENCING (NGS) FOR MINIMAL RESIDUAL DISEASE (MRD) AND CHIMERISM MONITORING IN MYELODYSPLASTIC SYNDROME (MDS) AFTER ALLOGENIC STEM CELL TRANSPLANTATION (ASCT)
por: Zamanillo, Irene, et al.
Publicado: (2023)

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
por: Flores-Montero, J, et al.
Publicado: (2017)

Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
por: Puig, Noemi, et al.
Publicado: (2021)

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials
por: Lopez-Anglada, Lucia, et al.
Publicado: (2018)

NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial
por: Rosa-Rosa, Juan Manuel, et al.
Publicado: (2022)

FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
por: Botta, Cirino, et al.
Publicado: (2022)

Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
por: Botta, Cirino, et al.
Publicado: (2023)

Expression of p53 protein isoforms predicts survival in patients with multiple myeloma
por: Rojas, Elizabeta A., et al.
Publicado: (2022)

A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility
por: Misiewicz-Krzeminska, Irena, et al.
Publicado: (2018)

Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations()
por: Lopez, Aurelio, et al.
Publicado: (2015)

Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes
por: Cedena, M. Teresa, et al.
Publicado: (2017)

Correction: Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes
por: Cedena, M. Teresa, et al.
Publicado: (2018)

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients
por: Medina, Alejandro, et al.
Publicado: (2020)

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel
por: Caers, J., et al.
Publicado: (2018)

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial
por: Puig, Noemí, et al.
Publicado: (2020)

Microbiological impact of three commercial laying hen housing systems
por: Jones, D. R., et al.
Publicado: (2014)

Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
por: Puertas, Borja, et al.
Publicado: (2023)

P1284: LIQUID BIOPSY BY ULTRA-DEEP SEQUENCING PLUS PET-TC MONITORING IN REAL-LIFE FOLLICULAR LYMPHOMA PATIENTS
por: Jiménez-Ubieto, A., et al.
Publicado: (2022)

Increased efficacy for in-house validation of real-time PCR GMO detection methods
por: Scholtens, I. M. J., et al.
Publicado: (2009)

P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1
por: Popat, R., et al.
Publicado: (2022)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
por: Rosiñol, Laura, et al.
Publicado: (2023)

Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group
por: Mosquera Orgueira, Adrian, et al.
Publicado: (2022)

Large-scale real-life analysis of survival and usage of therapies in multiple myeloma
por: Lopez-Muñoz, N., et al.
Publicado: (2023)

Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma
por: Lopez-Muñoz, N., et al.
Publicado: (2023)

Influence of commercial laying hen housing systems on the incidence and identification of Salmonella and Campylobacter
por: Jones, D. R., et al.
Publicado: (2016)

PB1781: THE APPLICATION OF CF-DNA FOR NGS MRD STUDIES IN PATIENTS WITH LMA IMPROVES THE SENSITIVITY OF THE METHOD WITH RESPECT TO CTC.
por: Sánchez-Redondo, Noemí Álvarez, et al.
Publicado: (2023)

Dectin-2 sensing of house dust mite is critical for the initiation of airway inflammation
por: Clarke, D L, et al.
Publicado: (2014)

NB housing study protocol: investigating the relationship between subsidized housing, mental health, physical health and healthcare use in New Brunswick, Canada
por: Woodhall-Melnik, J., et al.
Publicado: (2022)

An unexpected high-pressure stability domain for a lower density polymorph of benzophenone
por: Rietveld, I. B., et al.
Publicado: (2023)

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis
por: Cuenca, Isabel, et al.
Publicado: (2020)

P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Popat, R, et al.
Publicado: (2022)

P848: EXPRESSION PROFILE OF BCL-2 FAMILY PROTEINS IN MULTIPLE MYELOMA.
por: Sánchez, Cristina De Ramón, et al.
Publicado: (2023)

LIVING IN A DOLL HOUSE: A CASE REPORT AND LITERATURE REVIEW OF REDUPLICATIVE PARAMNESIA
por: Pinto, J. M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_crb3i7fid9mo8hq3nq05uo4g6p